Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL27692191 | 0.92 | — | — | |
| SCHEMBL27553773 | 0.91 | ALDH1A1 (0.54) | — | |
| SCHEMBL37752 | 0.91 | — | — | |
| Acetone SCHEMBL27712187 | 0.88 | ALDH1A1 (0.53) | — | |
| Acetic Acid Methyl Ester SCHEMBL31169134 | 0.88 | ALDH1A1 (0.77) | — | |
| SCHEMBL6352035 | 0.87 | — | — | |
| Rubidium SCHEMBL7045613 | 0.87 | — | — | |
| SCHEMBL18154634 | 0.87 | — | — | |
| SCHEMBL7045611 | 0.87 | — | — | |
| Water SCHEMBL17289280 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | claimed |
| CN-116706029-A | Double-layer coated graphite anode material and preparation method thereof | 江苏天合储能有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20180000792-A1 | MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME | BIONEVIA PHARMACEUTICALS INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9566269-B2 | Modified release compositions of epalrestat or a derivative thereof and methods for using the same | BIONEVIA PHARMACEUTICALS INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3042654-A1 | MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME | Bionevia Pharmaceuticals Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2665477-B1 | MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME | BIONEVIA PHARMACEUTICALS INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140296309-A1 | MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME | BIONEVIA PHARMACEUTICALS INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-8668932-B2 | Extended release venlafaxine formulation | ANDRX PHARMACEUTICALS, LLC (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2665477-A1 | MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME | Bionevia Pharmaceuticals Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012100208-A1 | MODIFIED RELEASE COMPOSITIONS OF EPALRESTAT OR A DERIVATIVE THEREOF AND METHODS FOR USING THE SAME | BIONEVIA PHARMACEUTICALS INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2005048923-A2 | EXTENDED RELEASE VENLAFAXINE FORMULATION | ANDRX PHARMACEUTICALS, LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050106248-A1 | Extended release venlafaxine formulation | ANDRX PHARMACEUTICALS, LLC | 2005-05-19 | — | — | US | disclosed |
| EP-1233761-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND COATS | ALZA Corporation (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001037815-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND | ALZA CORPORATION (US) | 2001-05-31 | — | — | WO | disclosed |
| US-5358721-A | Antiviral therapy | ALZA CORPORATION (US) | 1994-10-25 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |